TARDBP and proteostasis deficiencies: However, this remarkable capability is limited to proteinopathy specific alterations that do not always correspond with clinical outcomes (Marcus et al., 2014) and cannot assess comorbid pathologies such as Lewy Body Dementia, gross and micro infarcts, microhemorrhages, TDP-43 proteinopathy, and hippocampal sclerosis that are known from pathologic studies to affect 64%–80% brains with confirmed AD (Beach & Malek-Ahmadi, 2021).